Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 5/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13701678 | 0.84 | KAT6A (0.56) | IRAK4XDHSCN10AKAT6AMKNK1 | |
| SCHEMBL13701643 | 0.83 | KAT6A (0.54) | ABL1KAT6ACYP2C19 | |
| SCHEMBL31243020 | 0.83 | SCN10A (0.47) | ABL1IRAK4XDHSCN10AHPGDS | |
| SCHEMBL13701699 | 0.82 | ABL1 (0.55) | ABL1KAT6ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL18496602 | 0.79 | SCN10A (0.46) | SCN10A | |
| SCHEMBL2735676 | 0.78 | HCAR2 (0.56) | HPGDS | |
| SCHEMBL2370058 | 0.77 | HPGDS (0.41) | IRAK4HPGDSCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL10288898 | 0.77 | KDM4E (0.62) | CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL17665892 | 0.75 | IRAK4 (0.61) | IRAK4 | |
| SCHEMBL13701661 | 0.75 | ABL1 (0.56) | ABL1SCN10AHPGDSKAT6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | EPHX1, EPHX2, EPX | ABL1 4720/4885IRAK4 4581/4885XDH 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.